Multicentric Longitudinal Performance Monitoring of Different Prenatal Cell‐Free DNA Screening Technologies in Belgium
Prenatal cell‐free DNA screening is widely used to assess the risk of fetal trisomy 21, 18, and 13. Although commercial and laboratory‐developed tests (LDTs) show high accuracy in validation studies, real‐world longitudinal performance data are lacking.